(Q73189647)

English

Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group

scientific article published on 01 January 2000

In more languages

Statements

scholarly article

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11078237%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11078237%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

M Farnier

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11078237%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

S Dejager

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11078237%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

language of work or name

0 references

publication date

1 January 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11078237%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

American Journal of Cardiology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11078237%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

85

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11078237%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

53-57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11078237%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11078237%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

New lipid lowering drugs and new effects of old drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900606-2

7 January 2021

Statins: within-group comparisons, statin escape and combination therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900606-2

7 January 2021

Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900606-2

7 January 2021

Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900606-2

7 January 2021

Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900606-2

7 January 2021

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900606-2

7 January 2021

Fluvastatin: a review of its use in lipid disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900606-2

7 January 2021

Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900606-2

7 January 2021

High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900606-2

7 January 2021

Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900606-2

7 January 2021

Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900606-2

7 January 2021

Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900606-2

7 January 2021

Rhabdomyolysis after taking atorvastatin with gemfibrozil

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900606-2

7 January 2021

Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900606-2

7 January 2021

Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900606-2

7 January 2021

Identifiers

10.1016/S0002-9149(99)00606-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11078237%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11078237%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q73189647&oldid=1744310905"